XCNQNOVA
Market cap825kUSD
Nov 11, Last price
0.04CAD
Name
Nova Mentis Life Science Corp
Chart & Performance
P/E
—
P/S
41.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
37.75%
Rev. gr., 5y
0.00%
Revenues
28k
Net income
-1m
L-67.44%
CFO
-278k
L-80.78%
Earnings
Apr 07, 2025
Profile
Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 28 | |||||||||
Cost of revenue | 1,205 | 1,937 | 2,934 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (1,177) | (1,937) | (2,934) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 1,295 | (249) | ||||||||
Tax Rate | ||||||||||
NOPAT | (1,177) | (3,232) | (2,685) | |||||||
Net income | (1,224) -67.44% | (3,761) 54.44% | (2,435) -94.55% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 19 | 1,483 | ||||||||
BB yield | -0.65% | -10.86% | ||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 119 | |||||||||
Net debt | (8) | (267) | (754) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (278) | (1,444) | (1,946) | |||||||
CAPEX | 1 | |||||||||
Cash from investing activities | 30 | |||||||||
Cash from financing activities | 19 | 1,491 | ||||||||
FCF | (352) | (3,323) | (2,078) | |||||||
| Balance | ||||||||||
Cash | 8 | 267 | 219 | |||||||
Long term investments | 535 | |||||||||
Excess cash | 7 | 267 | 754 | |||||||
Stockholders' equity | (811) | 33 | 459 | |||||||
Invested Capital | 8 | |||||||||
ROIC | ||||||||||
ROCE | 145.19% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | 146,763 | 136,565 | 111,105 | |||||||
Price | 0.02 -80.00% | 0.10 81.82% | 0.06 -74.42% | |||||||
Market cap | 2,935 -78.51% | 13,656 123.48% | 6,111 -44.44% | |||||||
EV | 2,927 | 13,390 | 5,357 | |||||||
EBITDA | (1,174) | (1,933) | (2,929) | |||||||
EV/EBITDA | ||||||||||
Interest | 1,295 | |||||||||
Interest/NOPBT | ||||||||||